PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer

Researchers demonstrated that inhibition of cancer-intrinsic EZH2 promoted antitumor immunity in estrogen receptor a-positive breast cancer. EZH2 is a component of the PRC2 complex, which catalyzes trimethylation of histone H3 at lysine 27.